Evidence map›Paper›PMID 41744005›Full record

ArticleFrontiers in immunology2025

Long non-coding RNAs in response to Ebola virus vaccine-induced immunity.

Izabela Mamede, Thomaz Luschër-Dias, Isabelle Franco Moscardini, Patrícia Gonzales-Dias, Bárbara Marinho, Fernando Marcon, Thiago Dominguez Crespo Hirata, Michael Eichberg, Donata Medaglini, Ali M Harandi and 11 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Ebola virus exploits host lncRNAbioRxiv : the preprint server for biology · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Izabela MamedeDepartment of Biochemistry and Immunology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Thomaz Luschër-DiasDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, Universidade de São Paulo, São Paulo, Brazil.
Isabelle Franco MoscardiniBios-Therapy, Physiological Systems for Health S.p.A., Sansepolcro, Italy.
Patrícia Gonzales-DiasOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
Bárbara MarinhoDepartment of Biochemistry and Immunology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Fernando MarconLaboratory of Genetics and Molecular Cardiology (LGCM), InCor/Clinical Hospital FMUSP (HCMUSP), São Paulo, Brazil.
Thiago Dominguez Crespo HirataCentre of Omics Technologies (CTO), School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
Michael EichbergStrategic Alliances at Merck Research Laboratories, Boston, MA, United States.
Donata MedagliniDepartment of Medical Biotechnologies, Laboratory of Molecular Microbiology and Biotechnology, University of Siena, Siena, Italy.
Ali M HarandiDepartment of Microbiology & Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Claire-Anne SiegristCenter of Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Tom H M OttenhoffLeiden University Center of Infectious Diseases (LUCID), Leiden, Netherlands.
Francesco SantoroDipartimento di Biotecnologie Mediche, Università di Siena, Siena, Italy.
André GonçalvesOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
Daniela M FerreiraOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
Rafael PolidoroDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, United States.
Glória R FrancoDepartment of Biochemistry and Immunology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Paulo P AmaralINSPER Institute of Education and Research, São Paulo, Brazil.
Helder NakayaDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, Universidade de São Paulo, São Paulo, Brazil.
Marylyn M AddoInstitute for Infection Research and Vaccine Development (IIRVD), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
VSV-EBOPLUS Consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long noncoding RNAs (lncRNAs) have emerged as critical regulators of gene expression, yet their role in shaping human responses to vaccination remains largely uncharacterized. Here, we analyzed RNA-sequencing data from three independent human cohorts vaccinated with the rVSVΔG-ZEBOV-GP Ebola vaccine to profile lncRNA expression dynamics. Using differential expression analysis and correlation meta-analysis across cohorts, we identified an expression signature with several lncRNAs, including

Indexed as

Ebola (EBOV)lncRNARNAsystems biologyvaccine

Identifiers

PMID41744005
PMCPMC12929432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.